1-1 of 1
Peter Kang, MD
Close
Sort by
Journal Articles

Phase II Study of Gemtuzumab Ozogamycin (GO) and Cytarabine (ARA-C) in Patients with High Risk MDS and AML..

Peter Kang, MD, Karen Seiter, MD, Delong Liu, MD, PhD, Muhammad Arshad, MD, Anila Qureshi, MD, John Nelson, MD, Tauseef Ahmed, MD
Journal: Blood
Blood (2004) 104 (11): 4723.
https://doi.org/10.1182/blood.V104.11.4723.4723
Published: 2004